U.S. markets close in 2 hours 54 minutes

Bionano Genomics, Inc. (BNGO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.5000-0.0220 (-4.21%)
As of 1:06PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close0.5220
Open0.5150
Bid0.5014 x 4000
Ask0.5036 x 1100
Day's Range0.5000 - 0.5174
52 Week Range0.2500 - 1.3900
Volume3,478,960
Avg. Volume5,532,125
Market Cap76.593M
Beta (5Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Bionano Genomics and its Users Present the Saphyr System for Optical Genome Mapping and Various Advancements in Clinical Variant Detection at AMP 2020
    GlobeNewswire

    Bionano Genomics and its Users Present the Saphyr System for Optical Genome Mapping and Various Advancements in Clinical Variant Detection at AMP 2020

    SAN DIEGO, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the performance and application of its Saphyr system for optical genome mapping are being showcased at the Annual Meeting of the Association for Molecular Pathology (AMP), being held virtually at amp20.amp.org from November 16-20. AMP is widely recognized as the preeminent scientific society dedicated to advancing the clinical practice, science and excellence of molecular and genomic laboratory medicine. With over 2,500 members in over 50 countries working in the field of molecular pathology, its annual meeting is considered the prime event for presenting advances and technological innovations in molecular diagnostics to pathologists, laboratory directors and clinical professionals. The Annual Meeting of AMP carries an educational component that teaches pathologists and laboratory professionals about novel and emerging methods in molecular pathology. For the first time at the meeting this year, Bionano optical genome mapping was taught as a technique in molecular pathology in the Get AMPed! Virtual Course on testing modalities for genome structure analysis along with current standard of care methods such as karyotyping, FISH and microarray analysis.In other sections of the conference, the application of the Saphyr system in a growing number of clinical applications is being showcased in a Corporate Workshop presented by Bionano and in a poster presentation. These events cover the recent progress in applying Saphyr to an expanding array of diseases, including repeat expansion disorders such as amyotrophic lateral sclerosis (ALS), Fragile-X syndrome, Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD), and a variety of other complex genetic disorders and heme malignancies.Below is a listing of presentations at AMP 2020 featuring the use of Bionano’s optical genome mapping technology:Updates and Case Studies in Molecular Pathology – Get AMPed! Virtual Course Sunday, November 15, 2020 – 12:30 pm - 12:55 pm Testing Modalities to Look at Genome Structure: Conventional Cytogenetics, FISH and Chromosomal Microarray Analysis Yassmine Akkari, Ph.D., Legacy HealthAMP Corporate Workshop November 16-20, 2020 – On-Demand Next Generation Cytogenomics: High Resolution Structural Variation Detection by Optical Mapping Alex Hastie, Ph.D., Vice President Clinical Affairs, Bionano GenomicsAMP 2020 Abstracts/Posters – On-Demand TT34: Optical Mapping Enables High-Throughput Analysis of Pathogenic Repeats Ernest Lam, Ph.D., Senior Manager, Bioinformatics, Bionano Genomics Repetitive elements are abundant and diverse in the human genome. They are also genetically unstable. Repeat expansions and contractions could impact protein structure and gene regulation. They underlie disorders such as facioscapulohumeral muscular dystrophy (FSHD) and amyotrophic lateral sclerosis (ALS). However, sequence analysis of these regions can be challenging. Clinical laboratories often rely on Southern blotting, which is labor-intensive and typically requires radioactive staining. Optical mapping with Bionano Genome Imaging provides an alternative high-throughput workflow that overcomes these limitations.About Bionano Genomics Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and content of the presentations identified in this press release; the effectiveness and utility of Bionano’s technology in basic genetic research and clinical settings, including its clinical applications with respect to genetic disorders and heme malignancies; the capabilities of Bionano’s technology in comparison to other standard of care methods; and Bionano’s strategic plans. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. CONTACTS Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.comInvestor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC +1 (617) 430-7577 arr@lifesciadvisors.comMedia Contact: Darren Opland, PhD LifeSci Communications +1 (617) 733-7668 darren@lifescicomms.com

  • Bionano Genomics Reports Third Quarter 2020 Financial Results and Provides Business Update
    GlobeNewswire

    Bionano Genomics Reports Third Quarter 2020 Financial Results and Provides Business Update

    Company to host conference call today, November 12, at 4:30 pm ETSAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business, today reported its financial results for the third quarter ended September 30, 2020 and provided a business update. “We believe key events this quarter have set us up for continued growth and success,” said Erik Holmlin, Ph.D., CEO of Bionano. “Yesterday, in the largest Saphyr study on leukemia to date, cytogenetic thought leaders from leading U.S. institutions recommended that optical genome mapping using Saphyr be considered as a first-line diagnostic tool in leukemias. We saw continued adoption by cytogenomic labs around the world and for COVID host genome research, publication of several major studies on cancer genomics, genetic diseases and reference genome assembly, and made significant improvements to the Saphyr system. We enhanced our management team with the addition of our Chief Financial Officer and our first Chief Medical Officer. In addition, we completed the strategic acquisition of Lineagen, which adds to our revenue and outlines a potential path to reimbursement of laboratory developed tests performed on Saphyr.”Recent Business HighlightsThe Company continued building scientific momentum and driving utilization of its Saphyr System at key institutions across the globe, with the following notable announcements: * Multi-Center Evaluation of Bionano Optical Genome Mapping by Cytogenetics Thought Leaders in the US Led to Recommendation for Bionano’s Saphyr to Replace Karyotyping as First-Line Test for Detection and Identification of Structural and Copy Number Variants in Leukemia Patients   * Saphyr played essential role in identifying three previously unknown genetic mutation types in cancer in study from Weill Cornell   * Saphyr showed to be key to understanding cancer genome structures that make tumors grow aggressively   * Boston Children’s Hospital used Saphyr to study children with severe COVID-19 form MIS-C, and Rockefeller University used animal species susceptible and resistant to COVID-19 in Saphyr-based comparative genomics study to identify genome variants that predispose to infection   * Saphyr data provided insight and understanding of repeat expansion disorders causing muscular dystrophy and ALS, and was shown to be indispensable for analysis of microdeletion syndromes   * Vertebrate Genome Project ruled Bionano optical genome mapping technology as essential part of assembling reference quality genomes   * Expanded European business with adoption of Saphyr at three of Europe’s largest pediatric hospitals in Spain, Italy and France.   * Expanded Global business with adoption of Saphyr for Next-Generation Cytogenomics in Eastern Europe, Australia and Canada   * Saphyr received German accreditation of Laboratory Developed Test for genetic disease testingEnhanced Saphyr System * Released fast and simple DNA isolation protocol to process solid tumor samples   * Released largest ever update to its suite of software tools that simplifies clinical analysis, reduces time to actionable results and makes adoption by clinical labs easier   * Saphyr services offered in CLIA Certified Lab Expanded Bionano Genomics’ clinical applicationsCorporate * Acquired Diagnostics Services Provider Lineagen to Accelerate Clinical Adoption of Saphyr for Digital Cytogenetics, Expanded Diagnostic Testing Menu with Launch of Lineagen’s EpiPanelDx PLUS Gene Panel Test that Identifies Genetic Conditions Related to Epilepsy   * Announced positive outcome from a special shareholder meeting where stockholders voted in favor of the company’s proposal to increase the number of authorized shares of common stock   * Enhanced senior management team with the appointments of Christopher Stewart as Chief Financial Officer and Dr. Alka Chaubey as Chief Medical OfficerThird Quarter Ended 2020 Financial ResultsTotal Revenue. Total revenue was $2.2 million for the three months ended September 30, 2019, up 86% sequentially from $1.2M in the prior quarter. Third quarter revenue was down 33.7% compared to $3.3 million for the same period in 2019. The decrease was driven by a change in the mix of revenue between instrument sales and our reagent rental program. Revenue for the three months ended September 30, 2020 includes service revenue of $0.4 million from our recently acquired subsidiary, Lineagen, from the date of the acquisition of August 21, 2020 to September 30, 2020.Cost of Revenue. Total cost of revenue decreased by $0.9 million, or 38.5%, to $1.5 million for the three months ended September 30, 2020 compared to $2.4 million for the same period in 2019. The decrease was driven by a change in the mix of revenue between instrument sales and our reagent rental program. The decrease in cost was  partially offset by an increase in in cost of our consumables as the number of units sold increased 34%.  In addition, cost of service revenue increased by $0.2 million attributed to revenue generated by our recently acquired subsidiary, Lineagen, from the date of the acquisition of August 21, 2020 to September 30, 2020.Operating Expenses. Operating expenses were $11.0 million for the three months ended September 30, 2020, compared to $6.6 million for the same period in 2019. The change is primarily due to increased legal and accounting fees to support business operations and its international presence, including approximately $1.5 million in transaction costs associated with the Lineagen acquisition, and an increase in wage expenses as a result of the addition of the 33 employees from the Lineagen acquisition and increased headcount in the Company’s global sales and marketing teams and back-office support teams to assist with the growth of its world-wide product distribution. Reduced travel and trade show expenses, in response to COVID travel protocols, have partially offset the increases in wages and professional services.Cash and cash equivalents. At September 30, 2020, the Company had cash and cash equivalents of $18.9 million compared to cash and cash equivalents of $17.3 million at December 31, 2019.Nine Months Ended 2020 Financial ResultsTotal Revenue.  Total revenue was $4.5 million for the nine months ended September 30, 2020 compared to $7.3 million for the same period in 2019. The decrease is largely driven by customers temporarily shutting down their lab operations in response to the COVID-19 pandemic. In addition, the decrease was driven by a change in the mix of revenue between instrument sales and our reagent rental program.Cost of Revenue.  Total cost of revenue decreased by $2.2 million, or 42.5%, to $2.9 million for the nine months ended September 30, 2020 compared to $5.1 million for the same period in 2019. The decrease was driven by the reduction in revenue largely driven by customers temporarily shutting down their lab operations in response to the COVID-19 pandemic as well as a change in the mix of revenue between instrument sales and our reagent rental program. The cost reduction was  partially offset by an increase in consumable units sold of 70%.Operating Expenses.  Operating expenses were $29.0 million for the nine months ended September 30, 2020, compared to $21.0 million for the same period in 2019. Research and development expenses increased $0.7 million, or 10.4%, to $7.4 million for the nine months ended September 30, 2020 compared to $6.7 million for the same period in 2019. This is due to headcount additions to the Company’s development teams but partially offset by the salary reductions implemented in April 2020. In addition, the Company’s materials and supply expense increased during the nine months ended September 30, 2020 due to continued efforts to innovate on Saphyr. Selling and general administrative expenses increased by $7.3 million, or 51.4%, to $21.6 million for the nine months ended September 30, 2020 compared to $14.3 million for the same period in 2019. This is primarily due to an increase in overall wage expenses due to increased headcount. In addition to the 33 employees added from the Lineagen acquisition, the Company increased headcount to its global sales and marketing teams and back-office support teams to assist with the growth of its world-wide product distribution. Also, the Company incurred increased legal and accounting fees to support business operations and its international presence, including approximately $1.5 million in transaction costs associated with the Lineagen acquisition. Lastly, the Company recognized bad debt expense of $1.3 million during the nine months ended September 30, 2020.Conference Call & Webcast Details Date:Thursday November 12th Time:4:30 p.m. Eastern Time Toll Free:877-407-0784 International:201-689-8560 Conference ID:13712129 Webcast:http://public.viavid.com/index.php?id=142056 To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay in the Investors section of the Bionano website.About Bionano Genomics Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. For more information, visit www.bionanogenomics.com or www.lineagen.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the contribution of our OGM technology to the improved detection of diagnostic information in the patients with leukemia and other genetic diseases, current and future utilization or adoption of Saphyr by researchers, scientists and leading medical institutions; our contributions to and the outcomes of studies discussed in this press release; our integration of Lineagen into our combined business, including any benefits or synergies from such integration; our future operating and our financial performance; potential reimbursement of laboratory developed tests performed on Saphyr; and the advancement of our strategic plans. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; our inability to achieve the anticipated benefits from our acquisition of Lineagen; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.CONTACTS Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.comInvestor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC +1 (617) 430-7577 arr@lifesciadvisors.comMedia Contact: Darren Opland, PhD LifeSci Communications +1 (617) 733-7668 darren@lifescicomms.com  Bionano Genomics, Inc.   Consolidated Balance Sheets       (Unaudited)    September 30, 2020 December 31, 2019 Assets    Current assets:    Cash and cash equivalents$18,867,000  $17,311,000  Accounts receivable, net3,860,000  6,334,000  Inventory, net4,593,000  3,444,000  Prepaid expenses and other current assets1,920,000  1,169,000  Total current assets29,240,000  28,258,000  Property and equipment, net3,635,000  1,950,000  Intangible assets, net1,580,000  —  Goodwill6,941,000  —  Total assets$41,396,000  $30,208,000       Liabilities and stockholders’ equity    Current liabilities:    Accounts payable$5,665,000  $2,699,000  Accrued expenses4,466,000  3,225,000  Contract liabilities412,000  358,000  Current portion of long-term debt14,239,000  20,085,000  Total current liabilities24,782,000  26,367,000  Long-term debt, net of current portion1,775,000  —  Long-term contract liabilities88,000  183,000  Other non-current liabilities75,000  44,000  Total liabilities26,720,000  26,594,000  Commitments and contingencies    Stockholders’ equity:    Common stock, $0.0001 par value, 200,000,000 and 200,000,000 shares authorized at September 30, 2020 and December 31, 2019, respectively; 148,348,000 and 34,274,000 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively15,000  3,000  Additional paid-in capital146,613,000  106,188,000  Accumulated deficit(131,952,000) (102,577,000) Total stockholders’ equity14,676,000  3,614,000  Total liabilities and stockholders’ equity$41,396,000  $30,208,000         Bionano Genomics, Inc.   Consolidated Statements of Operations       Three Months Ended September 30, Nine Months Ended September 30,  2020 2019 2020 2019 Revenue:        Product revenue$1,580,000  $3,162,000  $3,503,000  $6,870,000  Service and other revenue616,000  151,000  1,010,000  470,000  Total revenue2,196,000  3,313,000  4,513,000  7,340,000  Cost of revenue:        Cost of product revenue1,137,000  2,238,000  2,427,000  4,883,000  Cost of service and other revenue324,000  137,000  493,000  194,000  Total cost of revenue1,461,000  2,375,000  2,920,000  5,077,000  Operating expenses:        Research and development2,304,000  2,174,000  7,379,000  6,682,000  Selling, general and administrative8,659,000  4,449,000  21,640,000  14,295,000  Total operating expenses10,963,000  6,623,000  29,019,000  20,977,000  Loss from operations(10,228,000) (5,685,000) (27,426,000) (18,714,000) Other expenses:        Interest expense(589,000) (578,000) (1,911,000) (1,613,000) Loss on debt extinguishment—  —  —  (1,333,000) Other expenses55,000  (131,000) —  (241,000) Total other expenses(534,000) (709,000) (1,911,000) (3,187,000) Loss before income taxes(10,762,000) (6,394,000) (29,337,000) (21,901,000) Provision for income taxes(30,000) (4,000) (40,000) (13,000) Net loss$(10,792,000) $(6,398,000) $(29,377,000) $(21,914,000)

  • Multi-Center Evaluation of Bionano Optical Genome Mapping by Cytogenetics Thought Leaders in the US Leads to Recommendation for Bionano’s Saphyr to Replace Karyotyping as First-Line Test for Detection and Identification of Structural and Copy Number Variants in Leukemia Patients
    GlobeNewswire

    Multi-Center Evaluation of Bionano Optical Genome Mapping by Cytogenetics Thought Leaders in the US Leads to Recommendation for Bionano’s Saphyr to Replace Karyotyping as First-Line Test for Detection and Identification of Structural and Copy Number Variants in Leukemia Patients

    * Saphyr detected all clinically relevant structural variants (SVs) and copy number variants (CNVs) in 100 AML samples making it 100% concordant with standard of care * Saphyr also detected additional clinically relevant SVs above and beyond standard of care in 11% of cases and refined the genomic structure analysis in another 13% of cases, which means Optical Genome Mapping (OGM) with Saphyr has the potential to change prognosis and patient management * Study authors are from leading institutions in the United States, including Augusta University, Columbia University, Fred Hutchinson Cancer Research Center, Mayo Clinic, MD Anderson Cancer Center and, Penn State University SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study led by cytogenetics experts from the nation’s top clinical and cancer centers in which they recommended that optical genome mapping (OGM) using Bionano’s Saphyr System be considered as a first-line test for detection and identification of clinically relevant structural variants and copy number variants in leukemias. The paper, published this week in medRxiv, describes detection and identification of structural variants and copy number variants in 100 patients with acute myeloid leukemia (AML). This study is the largest to-date in leukemia for Bionano and the first published study from the United States comparing Bionano’s OGM to karyotyping, the current standard of care in leukemia testing.The authors, who are cytogenetic leaders from prestigious institutions including Augusta University, Columbia University, Fred Hutchinson Cancer Center, Mayo Clinic, MD Anderson and Penn State University, reported that Saphyr detected 100% of all clinically relevant SVs and CNVs previously detected by standard of care methods and that Saphyr provided additional actionable data in 24% of the cases.Karyotyping, which provides a whole genome analysis of single cells, has been the standard of care for AML patients for decades. This study demonstrated several advantages of OGM over karyotyping with no obvious deficiencies in performance. The authors reported that the performance of OGM surpassed even the performance of karyotyping combined with other tests, such as fluorescence in situ hybridization (FISH) and chromosomal microarray, in a more refined and simplified workflow that was more cost effective than current methods.Erik Holmlin, Ph.D., CEO of Bionano Genomics commented, “This study is our flagship study in the United States. The authors come from leading institutions across the country and belong to the groups that influence what technologies are included in medical guidelines. While their finding of 100% concordance with standard of care is an important benchmark, the finding of incremental diagnostic information above and beyond the standard of care is what makes Saphyr compelling as a potential new standard in testing leukemia patients. We believe the authors’ recommendation to make Saphyr a first-line test for the detection and identification of clinically relevant genomic variants in AML and other leukemias indicates that Saphyr is ready for broad clinical adoption. We further believe that this study and others published like it form the basis of an important dossier that shows the clinical utility and validity of Bionano optical genome mapping, which we will be able use in connection with assays developed through our Lineagen business to outline a potential path to reimbursement of laboratory developed tests that are performed on Saphyr.”The publication is available at: https://www.medrxiv.org/content/10.1101/2020.11.07.20227728v1About Bionano Genomics Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the contribution of Bionano’s OGM technology to the improved detection of diagnostic information in patients with leukemia and other genetic diseases; the capabilities of Bionano’s OGM technology in comparison to other genome analysis technologies; Bionano’s beliefs regarding Saphyr’s readiness for broad clinical adoption; the ability of this study’s authors to influence what technologies are included in medical guidelines; our expectations regarding the utilization of Bionano OGM technology with assays developed through our Lineagen business; and Bionano’s strategic plans. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.CONTACTS Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.comInvestor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC +1 (617) 430-7577 arr@lifesciadvisors.comMedia Contact: Darren Opland, PhD LifeSci Communications +1 (617) 733-7668 darren@lifescicomms.com